title: COMparison of Platelet reactivity following prAsugrel and ticagrelor loading dose in ST-Segment elevation myocardial infarctION patients: The COMPASSION study.
abstract: Prasugrel and ticagrelor are potent P2Y12-ADP receptor antagonists which are superior to clopidogrel in acute coronary syndromes. To date no clinical trial directly compared these two drugs. Platelet reactivity correlates with ischemic and bleeding events in patients undergoing percutaneous coronary intervention. Recent pharmacological studies have observed a delayed onset of action of these two drugs in ST-segment elevation myocardial infarction (STEMI). We provide the first adequately powered pharmacological study comparing PR following ticagrelor and prasugrel loading dose (LD) in STEMI patients when the maximal biological effect is reached. In the present study, ticagrelor was associated with a lower rate of high on-treatment PR compared to prasugrel.
authors.affiliation: Service de Cardiologie, Centre Hospitalo-Universitaire Nord, Assistance-Publique Hôpitaux de Marseille , Chemin des Bourrely, Marseille , France .
authors.forename: Marc
authors.initials: M
authors.lastname: Laine
authors.forename: Mélanie
authors.initials: M
authors.lastname: Gaubert
authors.forename: Corinne
authors.initials: C
authors.lastname: Frère
authors.forename: Michael
authors.initials: M
authors.lastname: Peyrol
authors.forename: Franck
authors.initials: F
authors.lastname: Thuny
authors.forename: Serge
authors.initials: S
authors.lastname: Yvorra
authors.forename: Virginie
authors.initials: V
authors.lastname: Chelini
authors.forename: Bruno
authors.initials: B
authors.lastname: Bultez
authors.forename: Stephane
authors.initials: S
authors.lastname: Luigi
authors.forename: Zair
authors.initials: Z
authors.lastname: Mokrani
authors.forename: Jacques
authors.initials: J
authors.lastname: Bessereau
authors.forename: Richard
authors.initials: R
authors.lastname: Toesca
authors.forename: Anne
authors.initials: A
authors.lastname: Champenois
authors.forename: Françoise
authors.initials: F
authors.lastname: Dignat-George
authors.forename: Franck
authors.initials: F
authors.lastname: Paganelli
authors.forename: Laurent
authors.initials: L
authors.lastname: Bonello
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000368:Aged; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy*; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D010979:Platelet Function Tests; D000068799:Prasugrel Hydrochloride / Q000008:administration & dosage* / Q000493:pharmacokinetics; D058921:Purinergic P2Y Receptor Antagonists / Q000008:administration & dosage; D012307:Risk Factors; D000077486:Ticagrelor; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine
keywords: Platelet reactivity; ST-segment elevation myocardial infarction; VASP-index; prasugrel; ticagrelor